Clinical Trial Details

< Previous Trial     Next Trial >
Study ID ONC-MA-1001
Investigator
Senior Medical Director,   Astellas Pharma Global Development, Inc.
Title A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostrate Cancer and Men With Metastatic Prostate Cancer
Conditions Prostate Cancer
Metastatic Prostate Cancer
Castration-resistant Prostate Cancer
Interventions
Phase N/A
Purpose The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and trigger(s) for treatment changes and to document healthcare resource utilization used to manage treatment-related complications.
Eligibility Ages Eligible: N/A
Genders Eligible:  Male
Accepts Healthy Volunteers:  No
Inclusion Criteria:
  • Diagnosis of prostate adenocarcinoma
  • Will receive a new intervention at the time of study entry, for the treatment of: - Biochemical failure after initial curative-intent surgery (radical prostatectomy) or radiotherapy (external-beam radiation therapy, brachytherapy, or both) and a PSA doubling time of one year or less or a confirmed PSA of ≥ 50 ng/mL (2 consecutive values) within 6 months prior to study entry; or - Castration-resistant prostate cancer; or - Metastatic prostate cancer at initial diagnosis of prostate cancer Exclusion Criteria:
  • Prior treatment of metastatic castration-resistant prostate cancer with systemic chemotherapy
  • Life expectancy of <1 year due to comorbidities
  • Study Location N/A
    Contact Astellas Pharma Global Development, Inc.
    224-205-8800
    Astellas.registration@astellas.com
    Information obtained from ClinicalTrials.gov, on 7/7/2015. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
    Please refer to this study by its ClinicalTrials.gov identifier: NCT02066961


    Back to Search Results